Cite
MLA Citation
Sumanta Kumar Pal et al.. “Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.” Lancet, vol. 400, no. 10358, 2022, pp. 1103–1116. http://access.bl.uk/ark:/81055/vdc_100167536560.0x000050